Sponsor

SOLTI Breast Cancer Research Group

Clinical research sponsor

Published trials47
Recruiting shown10
Roles2
SourceClinicalTrials.gov

Clinical trials

47 shown
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity ManagementNCT07371585 · lead sponsor · 2026-02-18
RECRUITING
Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in SpainNCT06991946 · lead sponsor · 2025-05-20
RECRUITING
HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab GovitecanNCT06236269 · lead sponsor · 2024-03-15
RECRUITING
Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)NCT05885009 · lead sponsor · 2023-03-28
RECRUITING
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast CancerNCT05982093 · lead sponsor · 2023-02-03
RECRUITING
NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE TrialNCT05569811 · lead sponsor · 2022-11-25
ACTIVE_NOT_RECRUITING
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast CancerNCT05296746 · lead sponsor · 2022-05-03
ACTIVE_NOT_RECRUITING
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic SubtypeNCT05207709 · lead sponsor · 2022-03-28
TERMINATED
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.NCT05340413 · lead sponsor · 2022-03-25
COMPLETED
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsNCT04802876 · lead sponsor · 2021-04-12
ACTIVE_NOT_RECRUITING
Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast CancerNCT04759248 · lead sponsor · 2021-03-15
ACTIVE_NOT_RECRUITING
Elacestrant in Preoperative Setting, a Window of Opportunity StudyNCT04797728 · lead sponsor · 2021-02-09
COMPLETED
A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 ExpressionNCT04610528 · lead sponsor · 2020-12-22
UNKNOWN
Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast CancerNCT04142892 · lead sponsor · 2020-11-06
COMPLETED
Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast CancerNCT04497285 · lead sponsor · 2020-10-20
ACTIVE_NOT_RECRUITING
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast CancerNCT04460430 · lead sponsor · 2020-07-23
TERMINATED
Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor ProgressionNCT04251169 · lead sponsor · 2020-07-21
TERMINATED
Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BCNCT04142060 · lead sponsor · 2020-06-01
TERMINATED
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer PatientsNCT04253561 · lead sponsor · 2020-02-25
COMPLETED
Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant ChemotherapyNCT04130152 · lead sponsor · 2019-11-21
COMPLETED
Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast CancerNCT03802604 · lead sponsor · 2018-12-10
COMPLETED
Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.NCT03248427 · lead sponsor · 2017-07-13
COMPLETED
Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)NCT02802748 · lead sponsor · 2016-07-01
COMPLETED
Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast CancerNCT02448420 · lead sponsor · 2015-07-01
COMPLETED
SOLTI Breast Cancer Molecular Screening Program (AGATA)NCT02445482 · lead sponsor · 2014-10-01
COMPLETED
PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast CancerNCT01973660 · lead sponsor · 2013-10-01
COMPLETED
Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast CancerNCT01669239 · lead sponsor · 2013-06-01
COMPLETED
Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast CancerNCT01669252 · lead sponsor · 2012-08-01
COMPLETED
Sentinel Lymph Node Total Tumoral Load as a Predictor of Non Sentinel Node Involvement in Early Breast CancerNCT01669265 · lead sponsor · 2012-06-01
COMPLETED
A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast CancerNCT01629615 · lead sponsor · 2012-06-01
COMPLETED
Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 YearsNCT00563953 · lead sponsor · 2007-09-01
COMPLETED
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant RibociclibNCT07237256 · collaborator · 2025-12-18
RECRUITING
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBCNCT06078384 · collaborator · 2024-12-27
RECRUITING
Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast CancerNCT06446882 · collaborator · 2024-10-11
RECRUITING
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)NCT05512364 · collaborator · 2023-12-15
RECRUITING
Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILSNCT05451784 · collaborator · 2022-07-20
RECRUITING
A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in SpainNCT06764186 · collaborator · 2025-01-07
ACTIVE_NOT_RECRUITING
Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant TherapyNCT04578106 · collaborator · 2020-09-23
TERMINATED
Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.NCT04053322 · collaborator · 2019-08-26
ACTIVE_NOT_RECRUITING
Adjuvant Palbociclib in Elderly Patients With Breast CancerNCT03609047 · collaborator · 2019-06-14
ACTIVE_NOT_RECRUITING
A Window-of-opportunity Study of Pelareorep in Early Breast CancerNCT04102618 · collaborator · 2019-03-29
TERMINATED
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerNCT02947685 · collaborator · 2017-06-21
ACTIVE_NOT_RECRUITING
A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast CancerNCT02301988 · collaborator · 2015-02-17
COMPLETED
A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)NCT02273973 · collaborator · 2014-11-12
COMPLETED
NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast CancerNCT01816594 · collaborator · 2013-09-03
COMPLETED
Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer PatientsNCT01204125 · collaborator · 2010-09-01
COMPLETED
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) StudyNCT00553358 · collaborator · 2008-01-05
COMPLETED

Sponsor roles

lead sponsor31
collaborator16

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.